Jonathan Jones
Neurology · Lafayette, LANPI 1518385137
Payments from drug & device makers
Across 317 payments — averaging $37.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Pfizer$713
- Biohaven Pharmaceutical Holding Company Ltd.$503
- UCB, Inc.$311
- Amgen$296
- Biohaven Pharmaceuticals, Inc.$192
- plus $743 from 15 others
What the payments were for
- Speaking & faculty fees$7,12559%
- Food & beverage$4,80740%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $9,223 |
| Pfizer | 66 | $713 |
| Biohaven Pharmaceutical Holding Company Ltd. | 41 | $503 |
| UCB, Inc. | 14 | $311 |
| Amgen | 15 | $296 |
| Biohaven Pharmaceuticals, Inc. | 11 | $192 |
| Biogen | 11 | $191 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
| Greenwich Biosciences, Inc. | 2 | $86 |
| Lilly USA, LLC | 5 | $68 |
| Lundbeck LLC | 3 | $64 |
| Sanofi | 2 | $40 |
| AstraZeneca | 3 | $37 |
| CSL Behring | 2 | $34 |
| Novartis | 2 | $30 |
| Virtus Pharmaceuticals LLC | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$7,125
- NURTEC ODT$121
How this compares
$11,980 in reported general payments places this provider in the 70th percentile of 225 neurology providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 11 | $12,741 |
| Ondansetron OdtOndansetron | 71 | $2,447 |
| Pregabalin | 63 | $1,568 |
| Meclizine Hcl | 60 | $633 |
| Duloxetine Hcl | 42 | $529 |
| Gabapentin | 13 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $713 | $12,74111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 neurology providers in Louisiana.
Other neurology in Lafayette
- Oliver AchiLafayette$187K
- Fabian LugoLafayette$27K
- Kevin HargraveLafayette$21K
- Virginia KellnerLafayette$18K
- Sahil ThankiLafayette$18K
- Steven SnaticLafayette$15K
- Thomas PrivettLafayette$15K
- Adam ForemanLafayette$12K
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.